<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144758">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093585</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001685-42</org_study_id>
    <nct_id>NCT02093585</nct_id>
  </id_info>
  <brief_title>Tenofovir Abacavir Platelet Activation Study</brief_title>
  <acronym>TAPAS</acronym>
  <official_title>Changes in Coagulation and Platelet Reactivity in HIV-1 Infected Patients Switching Between Abacavir and Tenofovir Containing Antiretroviral Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan Gerstoft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: National Board of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some but not all observational studies have found that current exposure to abacavir is
      associated with increased risk of cardiovascular events such as myocardial infarction,
      stroke and cardiovascular death. This study aim to investigate possible adverse effect of
      abacavir on platelet reactivity, coagulation and endothelial activation in HIV-1 infected
      patients. The study is an open-labeled cross-over trial, where patients receiving
      antiretroviral therapy containing abacavir switch treatment to a regimen containing
      tenofovir and vice versa for a period of 90 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Differences in platelet aggregation (Multiplate) before and after switching between abacavir and tenofovir.</measure>
    <time_frame>before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in clot formation kinetics (thromboelastography) before and after switching between abacavir and tenofovir.</measure>
    <time_frame>before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of plasma lipids</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated partial thromboplastin time  (APTT)</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>international normalized ratio (INR)/Factor II, VII, X</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antithrombine</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High sensitivity C reactive protein (HS-CRP)</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble P-Selectin</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>soluble CD40 ligand (sCD40L)</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syndecan-1</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble E-selectin</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue plasminogen activator</measure>
    <time_frame>Before and after 90 days intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Tenofovir to abacavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abacavir to tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abacavir (600 mg QD)</intervention_name>
    <arm_group_label>Tenofovir to abacavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir (245 mg QD)</intervention_name>
    <arm_group_label>Abacavir to tenofovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  Can understand and sign written informed consent

          -  Received one of the above mentioned antiretroviral regimens continuously ≥ 6 months

          -  HIV RNA &lt; 400 copies/mL for ≥ 6 months

        Exclusion Criteria:

          -  Receiving anticoagulant therapy, adenosine diphosphate (ADP) receptor inhibitors,
             aspirin or nonsteroidal antiinflammatory drugs (NSAIDs)

          -  Previous ischemic heart disease, peripheral atherosclerotic disease or stroke

          -  Coagulation disorder (e.g. hemophilia, factor V Leiden mutation)

          -  Platelet count &lt; 150 x 109/L during the past 6 months from inclusion

          -  Estimated glomerular filtration rate (eGFR) &lt;70 during the past 6 months from
             inclusion

          -  Humane leukocyte antigen (HLA)-B*57:01 positive genotype

          -  Hepatitis B or C positive during the past year from inclusion

          -  Hypersensitivity to the active substances or to any of the excipients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Gerstoft, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederikke Rönsholt, MD</last_name>
    <phone>+45 35459744</phone>
    <email>frederikkefr@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet, Klinik for Infektionsmedicin og Reumatologi, 8622</name>
      <address>
        <city>Copenhagen Ø</city>
        <state>Copenhagen</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederikke Rönsholt, MD</last_name>
      <phone>+45 35459744</phone>
      <email>frederikkefr@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jan Gerstoft</investigator_full_name>
    <investigator_title>MD, DMSc, Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Abacavir</keyword>
  <keyword>Platelet activation</keyword>
  <keyword>Thromboelastography</keyword>
  <keyword>Coagulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
